Biologic drugs can effectively treat inflammatory bowel disease (IBD), but the cost of these products can be prohibitive. Biosimilars such as CT-P13 (Remsima, Inflectra), an infliximab biosimilar referencing Remicade, have the potential to drive down treatment costs and enhance access to biologics for the patients who need them.
Biologic drugs can effectively treat inflammatory bowel disease (IBD), but the cost of these products can be prohibitive. Biosimilars such as CT-P13 (Remsima, Inflectra), an infliximab biosimilar referencing Remicade, have the potential to drive down treatment costs and enhance access to biologics for the patients who need them.
During the Asian Pacific Digestive Week 2018 meeting, held November 15-18 in Seoul, Republic of Korea, researchers presented on the long-term efficacy and safety of CT-P13 in treating patients with IBD.
The retrospective, multicenter study was performed for 368 patients with IBD who received at least 3 infusions of CT-P13 at 16 hospitals in Korea between 2012 and 2016.
In total, 267 of the patients were naïve to anti—tumor necrosis factor (anti-TNF) treatment when they began taking the biosimilar, while 101 patients were switched from the reference product. Retention rates at year 1, year 3, and year 5 were 86.1%, 68.5%, and 58.7%, respectively, in the anti-TNF–naïve group. In the switched patients, the respective retention rates were 69.7%, 46.0%, and 26.7%, respectively.
Among anti-TNF—naïve patients who had Crohn disease (CD), rates of clinical response and clinical remission were 94.3% and 78.6% at week 14, 92.7% and 82.4% at year 1, and 76.8% and 72.2% at year 3. Among the anti-TNF–naïve patients with ulcerative colitis (UC), the corresponding rates were 85.6% and 42.6% at week 14, 80.0% and 59.8% at year 1, and 55.2% and 44.2% at year 3, respectively.
In the patients who switched from the reference infliximab, the clinical efficacy of CT-P13 was maintained in 84.6% of patients with CD and 65.2% of patients with UC.
In total, adverse events related to CT-P13 were observed in 11.9% of patients with CD and 8.5% of patients with UC.
The researchers concluded that the biosimilar has good long-term efficacy and that it was, overall, well tolerated in patients with IBD. According to the study’s authors, the biosimilar is “a comparable alternative” to Remicade in treating patients with IBD.
Reference
Kim NH, Park DI, Kim YS, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. Presented at Asian Pacific Digestive Week 2018, November 15-18, 2018; Seoul, Republic of Korea. Abstract EE-0388 (PE-0543). onlinelibrary.wiley.com/doi/10.1111/jgh.14488.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.